SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-18-010603
Filing Date
2018-08-09
Accepted
2018-08-09 17:01:41
Documents
49
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0618_actiniumpharma.htm 10-Q 536744
2 AMENDED AND RESTATED BYLAWS OF ACTINIUM PHARMACEUTICALS, INC., DATED AUGUST 8, 2 f10q0618ex3-1_actinium.htm EX-3.1 116310
3 EMPLOYMENT AGREEMENT, DATED AUGUST 8, 2018, BETWEEN SANDESH SETH AND ACTINIUM PH f10q0618ex10-1_actinium.htm EX-10.1 85978
4 EMPLOYMENT AGREEMENT, DATED AUGUST 8, 2018, BETWEEN STEVE O'LOUGHLIN AND ACTINIU f10q0618ex10-2_actinium.htm EX-10.2 23871
5 LETTER OF GBH CPAS, PC TO THE SECURITIES AND EXCHANGE COMMISSION DATED AUGUST 9, f10q0618ex16-1_actinium.htm EX-16.1 2397
6 CERTIFICATION f10q0618ex31i_actiniumpharm.htm EX-31.1 12013
7 CERTIFICATION f10q0618ex31ii_actiniumpharm.htm EX-31.2 12966
8 CERTIFICATION f10q0618ex32i_actiniumpharm.htm EX-32.1 4843
9 CERTIFICATION f10q0618ex32ii_actiniumpharm.htm EX-32.2 5889
16 GRAPHIC ex10i_001.jpg GRAPHIC 6412
17 GRAPHIC ex10-2_001.jpg GRAPHIC 10890
  Complete submission text file 0001213900-18-010603.txt   2523909

Data Files

Seq Description Document Type Size
10 XBRL INSTANCE FILE atnm-20180630.xml EX-101.INS 269212
11 XBRL SCHEMA FILE atnm-20180630.xsd EX-101.SCH 28061
12 XBRL CALCULATION FILE atnm-20180630_cal.xml EX-101.CAL 30432
13 XBRL DEFINITION FILE atnm-20180630_def.xml EX-101.DEF 119212
14 XBRL LABEL FILE atnm-20180630_lab.xml EX-101.LAB 228136
15 XBRL PRESENTATION FILE atnm-20180630_pre.xml EX-101.PRE 173969
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 181006177
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences